Obecure completes patient treatment in obesity trial
<p>The double-blinded, placebo-controlled, dose-ranging study enrolled 281 patients with a BMI ranging from 30-40 at 20 at clinical centers across the US. Subjects were randomized into one of
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).